Maryland
Requires Coverage of Comprehensive Biomarker Testing
Yes
Highlighted Disparity
Latino individuals in Maryland are least likely to be diagnosed early
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Maryland is 49.0 and significantly lower than the national rate of 52.8.
- Maryland ranks 15th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Maryland improved by 11%.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer in Maryland is 31.2%, which is significantly higher than the national rate of 29.7%.
- Maryland ranks 12th among the 39 states with survival data, placing it in the average tier.
- Over the last five years, the survival rate in Maryland improved by 20%.
Early Diagnosis:
- In Maryland, 28.2% of cases are caught at an early stage, which is not significantly different than the national rate of 28.1%.
- Maryland ranks 28th among the 50 states with data on early-stage diagnosis, placing it in the average tier.
- Over the last five years, the early diagnosis rate in Maryland improved by 12%.
Lung Cancer Treatment
Biomarker Coverage:
- Maryland was one of the 17 states that required insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Maryland ranked 7th (out of 49 states with available data) with 24.3% of cases undergoing surgery as part of the first course of treatment, which is significantly higher than the national rate of 20.7%.
- This places Maryland in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in Maryland improved by 10%.
No Treatment:
- Maryland ranked 17th (out of 49 states with available data) with 18.7% of cases not receiving any treatment, which is significantly lower than the national rate of 21.0%.
- This places Maryland in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in Maryland increased by 13%.
Screening
Screening for High Risk:
- In Maryland, 19.2% of those at high risk were screened, which is not significantly different than the national rate of 18.2%.
- Maryland ranks 20th among all states, placing it in the average tier.
Prevention
Tobacco Use:
- The 2023 smoking rate in Maryland is 9.1% and significantly lower than the national rate of 11.4%.
- Maryland ranks 6th among all states, placing it in the above average tier.
Radon Exposure:
- In Maryland, 20.8% of radon test results were at or above the action level recommended by the EPA.
- Maryland ranks 21st among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 47.8 per 100,000 population among Black individuals in Maryland, significantly lower than the rate of 54.2 among Black individuals nationally, and significantly lower than the rate of 54.1 among white individuals in Maryland.
- The five-year survival rate is 29.9% among Black individuals in Maryland, significantly higher than the rate of 27.1% among Black individuals nationally, and not significantly different than the rate of 31.4% among white individuals in Maryland.
- 25.6% of lung cancer cases are diagnosed at an early stage among Black individuals in Maryland, not significantly different than the rate of 25.1% among Black individuals nationally, and significantly lower than the rate of 29.6% among white individuals in Maryland.
- 21.4% of Black individuals with lung cancer in Maryland underwent surgery, significantly higher than the rate of 17.1% among Black individuals nationally, and significantly lower than the rate of 25.3% among white individuals in Maryland.
- 20.9% of Black individuals with lung cancer in Maryland did not receive any treatment, significantly lower than the rate of 22.7% among Black individuals nationally, and significantly higher than the rate of 18.1% among white individuals in Maryland.
Latino individuals:
- The rate of new lung cancer cases is 17.1 per 100,000 population among Latino individuals in Maryland, significantly lower than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 54.1 among white individuals in Maryland.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 22.8% of lung cancer cases are diagnosed at an early stage among Latino individuals in Maryland, not significantly different than the rate of 23.9% among Latino individuals nationally, and significantly lower than the rate of 29.6% among white individuals in Maryland.
- 27.8% of Latino individuals with lung cancer in Maryland underwent surgery, not significantly different than the rate of 21.4% among Latino individuals nationally, and not significantly different than the rate of 25.3% among white individuals in Maryland.
- 14.7% of Latino individuals with lung cancer in Maryland did not receive any treatment, significantly lower than the rate of 25.8% among Latino individuals nationally, and not significantly different than the rate of 18.1% among white individuals in Maryland.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 25.7 per 100,000 population among Asian or Pacific Islanders individuals in Maryland, significantly lower than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 54.1 among white individuals in Maryland.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 23.4% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Maryland, not significantly different than the rate of 23.7% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 29.6% among white individuals in Maryland.
- 26.1% of Asian or Pacific Islander individuals with lung cancer in Maryland underwent surgery, not significantly different than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 25.3% among white individuals in Maryland.
- 14.7% of Asian or Pacific Islander individuals with lung cancer in Maryland did not receive any treatment, significantly lower than the rate of 19.8% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 18.1% among white individuals in Maryland.
Indigenous Peoples:
- The rate of new lung cancer cases is 23.7 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Maryland, significantly lower than the rate of 39.8 among Indigenous Peoples nationally, and significantly lower than the rate of 54.1 among white individuals in Maryland.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Maryland due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Maryland falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Maryland was one of the states that required insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Maryland falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 7, 2025